Merck, maker of osteoporosis drug Fosamax, may have “seriously underreported” risks of jawbone death related to the drug, according to the American Association of Oral and Maxillofacial Surgeons. A class-action lawsuit has been filed claiming that Merck knew about the risk of jawbone death but hid it from the public.

Jawbone death related to the bisphosphonate class of drugs (to which Fosamax belongs), or Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ), is a serious side effect that destroys the bone in the jaw and is difficult to treat.

BRONJ was reported by oral surgeons, who noticed the condition among patients treated with intravenous forms of bisphosphonates, in 2003. A broader warning of BRONJ was issued for the entire class of drugs in 2005.

Fosamax is prescribed to about 10 million men and women — mostly postmenopausal women — each year to help increase bone density, with annual sales of $3 billion. Over 190 million prescriptions for oral bisphosphonate drugs have been dispensed worldwide.

 

We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.

Respectful, understanding, efficient and compassionate

Beasley Allen is one of the most professional organizations I have ever had the pleasure of working with. They are respectful, understanding, efficient, and above all compassionate. They take the best care of their clients in every way possible. They keep us informed and aware of things involved in their clients cases. Their counsel is stellar in the industry. I would highly recommend them to others in their time of need and I have done so.

—Chad H.